Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | DRD4 | P21917 | 10/20 | 0.53 |
| ▸ | DRD2 | P14416 | 9/20 | 0.53 |
| ▸ | DRD3 | P35462 | 9/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1728525 | 0.94 | DRD2 (0.59) | GAADRD4DRD2DRD3TAAR1 | |
| SCHEMBL6082947 | 0.93 | DRD4 (0.57) | GAADRD4DRD2DRD3 | |
| SCHEMBL1728633 | 0.92 | GAA (0.52) | GAADRD4DRD2DRD3TAAR1 | |
| SCHEMBL1727387 | 0.90 | MEN1 (0.53) | GAADRD4DRD2DRD3TAAR1 | |
| SCHEMBL1728589 | 0.87 | DRD2 (0.53) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL6081354 | 0.86 | DRD2 (0.56) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL1728672 | 0.85 | DRD2 (0.47) | GAADRD4DRD2DRD3TAAR1 | |
| SCHEMBL6080989 | 0.84 | DRD2 (0.50) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL1728536 | 0.83 | HTR1B (0.58) | DRD4DRD2DRD3MEN1KMT2A | |
| SCHEMBL1728578 | 0.82 | KDM4E (0.48) | DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551810-B1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-11-30 | — | — | EP | disclosed |
| EP-1551810-B1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-11-30 | — | — | EP | disclosed |
| US-7141561-B2 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-28 | — | — | US | disclosed |
| EP-1551810-A1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | Aventis Pharma Deutschland GmbH (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | US | disclosed |
| WO-2004012648-A2 | SUBSTITUTED DIARYL HETEROCYCLES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004011438-A1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | GPR119, GLP1R, SLC5A2 | GAA 401/4885DRD4 323/4885DRD2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.